Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: verdad who wrote (2690)	8/26/2003 2:06:32 PM
From: Ron	Read Replies (1) \| Respond to of 3576

Still more: =DJ Geron Up -2: Pdt Will Likely Hit Mkt In 2007-'08 -Analyst 26 Aug 10:39 By Jen Ryan Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Shares of Geron Corp. (GERN) jumped more than 8% Tuesday after the company was granted a patent that regulates the use of the human telomerase reverse transcriptase gene, or hTERT promoter, in cancer treatment. As a result of being granted the patent, the biopharmaceutical company will receive an undisclosed "milestone payment" from Cell Genesys Inc. (CEGE), the company that currently owns a non-exclusive license for the hTERT promoter, according to a press release. The hTERT promoter will be put into a virus, which will replicate and destroy cancer cells. Reni Benjamin, an analyst with Rodman & Renshaw Inc., said the next step is getting the promoter into clinical trial, adding that the company will file an Investigational New Drug Application (IND) by the end of 2003 or the beginning of 2004. The product will likely be released into the market between 2007 and 2008, when Benjamin said it will affect the company's bottom-line. For the six months ended June 30, Geron reported a loss of $17.2 million, or 63 cents a share, on total revenue of $547,000. Shares of Geron recently traded at $8.04, up 64 cents, or 8.6%, on volume of 1.7 million; its average daily turnover is 1.5 million shares. The stock hit a 52-week high of $9.75 in June, rebounding from a low of $1.41 in March.